Current status and future prospects in HMGB1 and receptor researches

Hideo Takahashi, Masahiro Nishibori

Research output: Contribution to journalReview article

Abstract

High mobility group box protein1 (HMGB1), a ubiquitous chromatin component, is released by necrotic cells, apoptotic cells, and cells in profound distress. HMGB1 plays a critical role as a proinflammatory mediator. HMGB1 represents an important new target for drug development in a variety of inflammatory disorders, including stroke, brain injury, arteriosclerosis, and cancer. The antibodies against HMGB1 and its receptors ar hopeful candidates for immunotherapeutic strategy for treating patients with these diseases. HMGB1 forms immunostimulatory complexes by interaction with cytokines and other endogenous or exogenous factors. The HMGB1-partner molecule complexes can enhance the immune response induced by the ligand alone. The current status of HMGB1 works is summarized and future prospects will be provided in this review.

Original languageEnglish
Pages (from-to)703-711
Number of pages9
JournalNihon rinsho. Japanese journal of clinical medicine
Volume74
Issue number4
Publication statusPublished - Apr 1 2016

Fingerprint

Research
Arteriosclerosis
Brain Neoplasms
Brain Injuries
Chromatin
Stroke
Cytokines
Ligands
Antibodies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current status and future prospects in HMGB1 and receptor researches. / Takahashi, Hideo; Nishibori, Masahiro.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 74, No. 4, 01.04.2016, p. 703-711.

Research output: Contribution to journalReview article

@article{b53e96db1aab473fbbecc836f375270e,
title = "Current status and future prospects in HMGB1 and receptor researches",
abstract = "High mobility group box protein1 (HMGB1), a ubiquitous chromatin component, is released by necrotic cells, apoptotic cells, and cells in profound distress. HMGB1 plays a critical role as a proinflammatory mediator. HMGB1 represents an important new target for drug development in a variety of inflammatory disorders, including stroke, brain injury, arteriosclerosis, and cancer. The antibodies against HMGB1 and its receptors ar hopeful candidates for immunotherapeutic strategy for treating patients with these diseases. HMGB1 forms immunostimulatory complexes by interaction with cytokines and other endogenous or exogenous factors. The HMGB1-partner molecule complexes can enhance the immune response induced by the ligand alone. The current status of HMGB1 works is summarized and future prospects will be provided in this review.",
author = "Hideo Takahashi and Masahiro Nishibori",
year = "2016",
month = "4",
day = "1",
language = "English",
volume = "74",
pages = "703--711",
journal = "Nippon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "4",

}

TY - JOUR

T1 - Current status and future prospects in HMGB1 and receptor researches

AU - Takahashi, Hideo

AU - Nishibori, Masahiro

PY - 2016/4/1

Y1 - 2016/4/1

N2 - High mobility group box protein1 (HMGB1), a ubiquitous chromatin component, is released by necrotic cells, apoptotic cells, and cells in profound distress. HMGB1 plays a critical role as a proinflammatory mediator. HMGB1 represents an important new target for drug development in a variety of inflammatory disorders, including stroke, brain injury, arteriosclerosis, and cancer. The antibodies against HMGB1 and its receptors ar hopeful candidates for immunotherapeutic strategy for treating patients with these diseases. HMGB1 forms immunostimulatory complexes by interaction with cytokines and other endogenous or exogenous factors. The HMGB1-partner molecule complexes can enhance the immune response induced by the ligand alone. The current status of HMGB1 works is summarized and future prospects will be provided in this review.

AB - High mobility group box protein1 (HMGB1), a ubiquitous chromatin component, is released by necrotic cells, apoptotic cells, and cells in profound distress. HMGB1 plays a critical role as a proinflammatory mediator. HMGB1 represents an important new target for drug development in a variety of inflammatory disorders, including stroke, brain injury, arteriosclerosis, and cancer. The antibodies against HMGB1 and its receptors ar hopeful candidates for immunotherapeutic strategy for treating patients with these diseases. HMGB1 forms immunostimulatory complexes by interaction with cytokines and other endogenous or exogenous factors. The HMGB1-partner molecule complexes can enhance the immune response induced by the ligand alone. The current status of HMGB1 works is summarized and future prospects will be provided in this review.

UR - http://www.scopus.com/inward/record.url?scp=84979096328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979096328&partnerID=8YFLogxK

M3 - Review article

VL - 74

SP - 703

EP - 711

JO - Nippon rinsho. Japanese journal of clinical medicine

JF - Nippon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 4

ER -